EyePoint Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
EYPT$0.36+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands except share data)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $281,263 | $95,633 |
| Marketable securities | 49,787 | 48,928 |
| Accounts and other receivables, net | 805 | 15,503 |
| Prepaid expenses and other current assets | 9,039 | 9,858 |
| Inventory | 3,906 | 2,886 |
| Total current assets | 344,800 | 172,808 |
| Property and equipment, net | 5,251 | 1,360 |
| Operating lease right-of-use assets | 4,983 | 6,038 |
| Restricted cash | 150 | 150 |
| Total assets | $355,184 | $180,356 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $6,504 | $5,919 |
| Accrued expenses | 17,521 | 16,359 |
| Deferred revenue | 38,592 | 1,205 |
| Short-term borrowings | — | 10,475 |
| Other current liabilities | 646 | 579 |
| Total current liabilities | 63,263 | 34,537 |
| Long-term debt | — | 29,310 |
| Deferred revenue – noncurrent | 20,692 | 13,557 |
| Operating lease liabilities – noncurrent | 4,906 | 5,984 |
| Other long-term liabilities | — | 600 |
| Total liabilities | 88,861 | 83,988 |
| Contingencies (Note 17) | ||
| Stockholders' equity: | ||
| Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding | — | — |
| Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2023and 2022, respectively; 49,043,074 and 34,082,934 shares issued and outstanding atDecember 31, 2023 and 2022, respectively | 49 | 34 |
| Additional paid-in capital | 1,007,556 | 766,899 |
| Accumulated deficit | (742,146) | (671,351) |
| Accumulated other comprehensive income | 864 | 786 |
| Total stockholders' equity | 266,323 | 96,368 |
| Total liabilities and stockholders' equity | $355,184 | $180,356 |
| — | — | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.